Industry & Policy News

[University of Toronto] University Professor Molly Shoichet has been named the inaugural Pamela and Paul Austin Chair in Precision and Regenerative Medicine

[University of Texas San Antonio] The University of Texas Health Science Center at San Antonio School of Dentistry is preparing to launch its Center for Regenerative Sciences, a new research initiative that aims to position the university at the forefront of regenerative dentistry and medicine.

[Fortune] Novo Nordisk was the company of 2023, soaring to the mantle of Europe’s most valuable company as its bumper weight-loss-aiding drug Ozempic flew off pharmacy shelves and shaved several inches off consumers’ waistlines. That is, provided its U.S. customers could first cough up the exorbitant price.

[University of Glasgow] The University of Glasgow, alongside NHS Greater Glasgow & Clyde, has opened the PRIMUS-006 pancreatic cancer study, part of the Precision-Panc Platform. The Phase II study will evaluate a new drug combination – gemcitabine, pembrolizumab, and IMM-101, as first-line treatment in patients with metastatic pancreatic cancer.

[Xylyx Bio, Inc. (BioSpace)] Xylyx Bio, Inc. announced that it has been awarded a Small Business Innovation Research (SBIR) Fast-Track grant from the National Cancer Institute of the National Institutes of Health (NIH) to advance commercial development of its InMatrico® disease modeling and drug testing platform to help scientists discover and test drug candidates for metastatic breast cancer.

[Life Science Newswire] Asgard Therapeutics announced it selected Exothera S.A., a leading provider of nucleic acids and viral vector development and manufacturing services, for process development up to clinical Phases I/II manufacturing of its candidate AT-108, based on viral vector technology.